The United Kingdom and the United States have agreed to a landmark commercial pact that will guarantee no tariffs on UK medicine products going into the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has pledged to increase funding on pharmaceuticals through the NHS. This pledge ensures that import taxes on these vital goods will be held at zero for a timeframe of 36 months.
This agreement is in response to recent warnings to significantly raise import taxes on branded pharmaceutical products, with potential rates discussed as high as double the cost.
"This deal with the Britain strengthens the international landscape for new treatments and introduces much-needed balance to transatlantic medicine commerce," a release noted.
Economic Importance
Medicines represent one of the the United Kingdom's biggest exports to the America, which is clearly the primary market for leading companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period prior to September, the UK sold drugs valued at £11.1bn to the US. This value represented nearly one-fifth of British export trade in that period.
"This deal safeguards work, increases capital expenditure and paves the way for the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Specific UK Commitments
The pact entails several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it judges new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a target to raise total NHS spending on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The sum manufacturers must return to the NHS to stay within budget will be restricted at fifteen percent. In the past, repayments topped twenty percent.
Industry Background
The pact takes place against a protracted row between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
The disagreement were exacerbated by assertions that US customers were paying significantly more for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been halted or scrapped, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
The Science Minister stated that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the past decade.
